Taho Pharmaceuticals Ltd. (TPEX:6467)

Market Cap	11.48B +31.4%
Revenue (ttm)	1.98M -74.5%
Net Income	-238.34M
EPS	-4.58
Shares Out	52.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	545,014
Open	225.50
Previous Close	227.50
Day's Range	212.00 - 227.50
52-Week Range	100.50 - 302.00
Beta	-0.94
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage. The company also develops TAH2211 Buprenorphine/Naloxone ...

• Industry: Pharmaceutical Preparations
• Founded: 2010
• Employees: 35
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6467

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 16, 2026

Data Sources Report a data error